|
Cardiomyopathies
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In conclusion, the P209L mutation in Bag3 does not cause cardiomyopathy in mice up to 16 mo of age under baseline conditions.
|
30499714 |
2019 |
|
Cardiomyopathies
|
0.100 |
Biomarker
|
group |
BEFREE |
Mutations in BAG3 are associated with dilated cardiomyopathy (DCM), but only a small number of cases have been reported to date, and the natural history of BAG3 cardiomyopathy is poorly understood.
|
30442290 |
2018 |
|
Cardiomyopathies
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Association of Variants in BAG3 With Cardiomyopathy Outcomes in African American Individuals.
|
30140897 |
2018 |
|
Cardiomyopathies
|
0.100 |
Biomarker
|
group |
BEFREE |
This case illustrates that counseling of patients with BAG3 myopathy should not predict an inevitable occurrence of cardiomyopathy.
|
30061062 |
2018 |
|
Cardiomyopathies
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Seven of 42 patients (16.7%) carried rare biallelic (homozygous or compound heterozygous) nonsynonymous or splice-site variations in 6 cardiomyopathy-associated genes (BAG3, DSP, PKP2, RYR2, SCN5A, or TNNI3).
|
28359509 |
2017 |
|
Cardiomyopathies
|
0.100 |
Biomarker
|
group |
BEFREE |
Earlier studies have ascribed a role for BAG3 in the development of cardiomyopathy in experimental animals leading to the identification of BAG3 mutations in patients with heart failure which may play a part in the onset of disease development and progression.
|
27381181 |
2017 |
|
Cardiomyopathies
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Our findings suggest that the variants in TNNT2 and BAG3 are associated with a high propensity to life-threatening cardiomyopathy presenting from childhood and young adulthood.
|
28669108 |
2017 |
|
Cardiomyopathies
|
0.100 |
Biomarker
|
group |
BEFREE |
To model BAG3 cardiomyopathy in a human system, we generated an isogenic series of human induced pluripotent stem cells (iPSCs) with loss-of-function mutations in BAG3.
|
28724793 |
2017 |
|
Cardiomyopathies
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Loss-of-function mutations in co-chaperone BAG3 destabilize small HSPs and cause cardiomyopathy.
|
28737513 |
2017 |
|
Cardiomyopathies
|
0.100 |
Biomarker
|
group |
BEFREE |
Our findings that BAG3 is localized at the sarcolemma and t-tubules while modulating myocyte contraction and action potential duration through specific interaction with the β1-adrenergic receptor and L-type Ca(2+) channel provide novel insight into the role of BAG3 in cardiomyopathies and increased arrhythmia risks in heart failure.
|
26796036 |
2016 |
|
Cardiomyopathies
|
0.100 |
Biomarker
|
group |
BEFREE |
BAG3 ablation in mice results in a lethal cardiomyopathy soon after birth and mutations of this gene have been associated with different cardiomyopathies including stress-induced Takotsubo cardiomyopathy (TTC).
|
26512958 |
2015 |
|
Cardiomyopathies
|
0.100 |
GeneticVariation
|
group |
BEFREE |
BAG3 myofibrillar myopathy presenting with cardiomyopathy.
|
25728519 |
2015 |
|
Cardiomyopathies
|
0.100 |
Biomarker
|
group |
BEFREE |
BCL-2-associated athanogene 3 (BAG3) is a protein implicated in the cardiomyocyte stress response and genesis of cardiomyopathy.
|
25753466 |
2015 |